Antithrombin_NP III_NP in_IN patients_NNS admitted_VBN to_TO intensive_JJ care_NN units_NNS :_: a_DT multicenter_NN observational_JJ study_NN Abstract_NP |_SYM Introduction_NN |_SYM The_DT administration_NN of_IN antithrombin_NP III_NP (_( ATIII_NP )_) is_VBZ useful_JJ in_IN patients_NNS with_IN congenital_JJ deficiency_NN ,_, but_CC evidence_NN for_IN the_DT other_JJ therapeutic_JJ indications_NNS of_IN this_DT drug_NN is_VBZ still_RB uncertain_JJ ._SENT In_IN Italy_NP ,_, the_DT use_NN of_IN ATIII_NP is_VBZ very_RB common_JJ in_IN intensive_JJ care_NN units_NNS (_( ICUs_NP )_) ._SENT For_IN this_DT reason_NN we_PP undertook_VBD an_DT observational_JJ study_NN to_TO determine_VB the_DT pattern_NN of_IN use_NN of_IN ATIII_NP in_IN ICUs_NP and_CC to_TO assess_VB the_DT outcome_NN of_IN patients_NNS given_VBN this_DT treatment_NN ._SENT Methods_NNS |_SYM From_IN 20_CD May_NP to_TO 20_CD July_NP 2001_CD all_DT consecutive_JJ patients_NNS admitted_VBN to_TO ICUs_NP in_IN 20_CD Italian_JJ hospitals_NNS and_CC treated_VBN with_IN ATIII_NP were_VBD enrolled_VBN ._SENT The_DT following_VBG information_NN was_VBD recorded_VBN from_IN each_DT patient_NN :_: congenital_JJ deficiency_NN ,_, indication_NN for_IN use_NN of_IN ATIII_NP ,_, daily_JJ dose_NN and_CC duration_NN of_IN ATIII_NP treatment_NN ,_, outcome_NN of_IN hospitalization_NN (_( alive_JJ or_CC dead_JJ )_) ._SENT The_DT outcome_NN data_NNS of_IN our_PP$ observational_JJ study_NN were_VBD compared_VBN with_IN those_DT reported_VBN in_IN previously_RB published_VBN randomized_VBN controlled_JJ trials_NNS (_( RCTs_NP )_) ._SENT Results_NNS |_SYM Two_NP hundred_CD and_CC sixteen_CD patients_NNS were_VBD enrolled_VBN in_IN the_DT study_NN ._SENT The_DT clinical_JJ indications_NNS for_IN using_VBG ATIII_NP were_VBD sepsis_NN (_( 25.9_CD %_NN )_) ,_, disseminated_VBN intravascular_JJ coagulation_NN (_( 23.1_CD %_NN )_) ,_, and_CC other_JJ clinical_JJ conditions_NNS (_( 46.8_CD %_NN )_) ._SENT At_IN the_DT end_NN of_IN the_DT study_NN ,_, 65.3_CD %_NN of_IN the_DT patients_NNS were_VBD alive_JJ ,_, 24.5_CD %_NN died_VBD and_CC 10.2_CD %_NN were_VBD still_RB in_IN the_DT hospital_NN ._SENT Among_IN the_DT patients_NNS with_IN sepsis_NN (_( n_NN =_SYM 56_CD )_) ,_, 19_CD died_VBD during_IN the_DT observation_NN period_NN (_( 33.9_CD %_NN ;_: 95_CD %_NN confidence_NN interval_NN 22.1_CD --_: 47.5_CD %_NN )_) ._SENT Discussion_NN |_SYM Our_JJ study_NN described_VBD the_DT pattern_NN of_IN use_NN of_IN ATIII_NP in_IN Italian_JJ hospitals_NNS and_CC provided_VBN information_NN on_IN the_DT outcome_NN of_IN the_DT subgroup_NN treated_VBN with_IN sepsis_NN ._SENT A_DT meta-analysis_NN of_IN current_JJ data_NNS from_IN RCTs_NP ,_, together_RB with_IN our_PP$ findings_NNS ,_, indicates_VBZ that_IN there_EX is_VBZ no_DT sound_JJ basis_NN for_IN using_VBG this_DT drug_NN in_IN ICU_NP patients_NNS with_IN sepsis_NN ._SENT antithrombin_NP III_NP ,_, disseminated_VBN intravascular_JJ coagulation_NN ,_, sepsis_NN ,_, septic_JJ shock_NN ,_, Antithrombin_NP III_NP (_( ATIII_NP )_) is_VBZ a_DT recognized_VBN treatment_NN for_IN patients_NNS with_IN congenital_JJ ATIII_NP deficiency_NN (_( see_VB also_RB the_DT approval_NN of_IN this_DT indication_NN by_IN the_DT Food_NP and_CC Drug_NP Administration_NP )_) ;_: in_IN contrast_NN ,_, the_DT evidence_NN supporting_VBG its_PP$ use_NN for_IN other_JJ clinical_JJ indications_NNS is_VBZ uncertain_JJ ._SENT In_IN Italian_JJ hospitals_NNS this_DT drug_NN is_VBZ widely_RB used_VBN in_IN patients_NNS admitted_VBN to_TO intensive_JJ care_NN units_NNS (_( ICUs_NP )_) ,_, who_WP are_VBP generally_RB given_VBN ATIII_NP for_IN the_DT treatment_NN of_IN sepsis_NN or_CC disseminated_VBN intravascular_JJ coagulation_NN (_( DIC_NP )_) ._SENT The_DT approval_NN of_IN ATIII_NP by_IN the_DT Italian_JJ Ministry_NP of_IN Health_NP was_VBD granted_VBN nearly_RB 10_CD years_NNS ago_RB (_( before_IN the_DT profound_JJ reform_NN of_IN the_DT Drug_NP Regulatory_NP Agency_NP made_VBD by_IN the_DT Italian_JJ Ministry_NP of_IN Health_NP in_IN 1993_CD )_) and_CC has_VBZ remained_VBN unchanged_JJ since_IN then_RB ._SENT This_DT approval_NN of_IN ATIII_NP was_VBD rather_RB generic_JJ and_CC included_VBN '_'' congenital_JJ deficiency_NN of_IN ATIII_NP and_CC all_DT clinical_JJ conditions_NNS that_WDT can_MD cause_VB an_DT acquired_VBN deficiency_NN of_IN ATIII_NP '_POS ._SENT Three_CD small_JJ randomized_VBN studies_NNS and_CC one_CD large_JJ international_JJ trial_NN assessed_VBD the_DT effectiveness_NN of_IN ATIII_NP in_IN sepsis_NN ,_, but_CC none_NN of_IN these_DT trials_NNS found_VBD a_DT significant_JJ benefit_NN in_IN terms_NNS of_IN reduced_VBN morbidity_NN or_CC mortality_NN ._SENT As_RB regards_VBZ congenital_JJ deficiency_NN ,_, the_DT effectiveness_NN of_IN ATIII_NP is_VBZ fairly_RB well_RB documented_VBN ,_, but_CC these_DT patients_NNS are_VBP rare_JJ ._SENT The_DT other_JJ clinical_JJ indications_NNS (_( such_JJ as_IN acute_JJ thrombosis_NN or_CC thromboembolism_NN ,_, prevention_NN of_IN DIC_NP in_IN hepatic_JJ coma_NN ,_, and_CC treatment_NN of_IN bleeding_VBG episodes_NNS in_IN cirrhosis_NN )_) are_VBP supported_VBN by_IN a_DT small_JJ series_NN of_IN very_RB preliminary_JJ studies_NNS (_( see_VB ,_, for_IN example_NN ,_, the_DT Drugdex_NP databank_NP ,_, CD-ROM_NP Drugdex_NP ,_, volume_NN 110_CD ;_: Micromedex_NP ,_, Englewood_NP ,_, Colorado_NP ,_, USA_NP )_) ._SENT To_TO achieve_VB a_DT better_JJR definition_NN of_IN the_DT current_JJ use_NN of_IN ATIII_NP in_IN Italian_JJ hospitals_NNS and_CC to_TO generate_VB naturalistic_JJ data_NNS (_( based_VBN on_IN routine_JJ practice_NN )_) about_IN the_DT outcome_NN of_IN this_DT treatment_NN ,_, we_PP undertook_VBD a_DT multicenter_NN observational_JJ study_NN ._SENT Design_NN of_IN the_DT study_NN and_CC aims_NNS |_SYM The_DT study_NN was_VBD based_VBN on_IN a_DT multicenter_NN observational_JJ design_NN ._SENT From_IN 20_CD May_NP to_TO 20_CD July_NP 2001_CD all_DT consecutive_JJ patients_NNS admitted_VBN to_TO ICUs_NP in_IN 20_CD Italian_JJ hospitals_NNS and_CC treated_VBN with_IN ATIII_NP were_VBD enrolled_VBN in_IN the_DT study_NN ._SENT The_DT study_NN had_VBD the_DT following_NN aims_VBZ :_: (_( 1_LS )_) surveying_VBG the_DT use_NN of_IN ATIII_NP in_IN patients_NNS admitted_VBN to_TO ICUs_NN ;_: (_( 2_LS )_) determining_VBG the_DT outcome_NN of_IN patients_NNS treated_VBN with_IN ATIII_NP ;_: and_CC (_( 3_LS )_) comparing_VBG the_DT results_NNS obtained_VBN from_IN our_PP$ observational_JJ study_NN with_IN those_DT previously_RB found_VBN in_IN the_DT randomized_VBN controlled_JJ trials_NNS (_( RCTs_NP )_) ._SENT A_DT meta-analysis_NN was_VBD also_RB conducted_VBN to_TO summarize_VB the_DT information_NN deriving_VBG from_IN four_CD RCTs_NNS that_WDT studied_VBD the_DT effectiveness_NN of_IN ATIII_NP in_IN sepsis_NN ._SENT Data_NNS collection_NN |_SYM The_DT following_VBG information_NN was_VBD recorded_VBN from_IN each_DT patient_NN enrolled_VBN in_IN the_DT study_NN :_: (_( 1_LS )_) demographic_JJ characteristics_NNS (_( age_NN ,_, sex_NN ,_, weight_NN )_) ;_: (_( 2_LS )_) congenital_JJ deficiency_NN (_( y/n_NN )_) ;_: (_( 3_LS )_) baseline_JJ ATIII_NP level_NN ;_: (_( 4_LS )_) ward_VB of_IN first_JJ admission_NN in_IN the_DT hospital_NN ;_: (_( 5_LS )_) clinical_JJ indication_NN for_IN using_VBG ATIII_NP (_( sepsis_NN or_CC DIC_JJ or_CC any_DT other_JJ clinical_JJ condition_NN )_) ;_: (_( 6_CD )_) daily_JJ dose_NN and_CC duration_NN of_IN treatment_NN with_IN ATIII_NP ;_: (_( 7_CD )_) outcome_NN of_IN hospitalization_NN (_( alive_JJ or_CC dead_JJ )_) ;_: and_CC (_( 8_CD )_) concurrent_JJ administration_NN of_IN antibiotics_NNS and/or_CC heparin_NN ._SENT Analysis_NN |_SYM The_DT information_NN collected_VBN from_IN each_DT patient_NN was_VBD analyzed_VBN by_IN standard_JJ descriptive_JJ statistics_NNS ._SENT In_IN the_DT subgroup_NN of_IN patients_NNS with_IN sepsis_NN ,_, the_DT in-hospital_JJ mortality_NN rate_NN observed_VBD in_IN our_PP$ study_NN was_VBD compared_VBN with_IN that_DT previously_RB reported_VBN by_IN the_DT four_CD RCTs_NP ._SENT All_DT rates_NNS were_VBD presented_VBN together_RB with_IN their_PP$ 95_CD %_NN confidence_NN interval_NN (_( CI_NP )_) ,_, which_WDT was_VBD calculated_VBN by_IN using_VBG Equations_NNS 1.26_CD and_CC 1.27_CD of_IN Fleiss_NP ._SENT The_DT overall_JJ number_NN of_IN patients_NNS who_WP were_VBD admitted_VBN to_TO ICUs_NP during_IN the_DT study_NN period_NN was_VBD 1648_CD ._SENT Of_IN these_DT patients_NNS ,_, 216_CD (_( 13_CD %_NN )_) were_VBD enrolled_VBN in_IN our_PP$ study_NN ._SENT The_DT characteristics_NNS of_IN these_DT 216_CD patients_NNS are_VBP presented_VBN in_IN Table_NP ._SENT Table_NP 1_CD |_SYM Characteristics_NN of_IN the_DT 216_CD patients_NNS enrolled_VBN in_IN our_PP$ observational_JJ study_NN and_CC of_IN the_DT subgroup_NN of_IN 56_CD patients_NNS treated_VBN for_IN sepsis_NN The_DT clinical_JJ indication_NN for_IN using_VBG ATIII_NP was_VBD sepsis_NN (_( n_NN =_SYM 56_CD )_) ,_, DIC_NP (_( n_NN =_SYM 50_CD )_) ,_, or_CC other_JJ (_( n_NN =_SYM 101_CD )_) ._SENT Table_NN also_RB reports_VBZ separate_JJ information_NN for_IN the_DT subgroup_NN of_IN 56_CD patients_NNS treated_VBN for_IN sepsis_NN ._SENT The_DT duration_NN of_IN ATIII_NP therapy_NN did_VBD not_RB differ_VB at_IN levels_NNS of_IN statistical_JJ significance_NN between_IN patients_NNS treated_VBN for_IN different_JJ clinical_JJ indications_NNS (_( P_NN =_SYM 0.57_CD according_VBG to_TO an_DT analysis_NN of_IN variance_NN )_) ._SENT The_DT daily_JJ dose_NN of_IN ATIII_NP showed_VBD a_DT difference_NN between_IN sepsis_NN and_CC other_JJ indications_NNS ._SENT Table_NN reports_VBZ the_DT outcome_NN of_IN hospitalization_NN according_VBG to_TO clinical_JJ indication_NN ._SENT With_IN regard_NN to_TO the_DT use_NN of_IN ATIII_NP in_IN patients_NNS with_IN sepsis_NN ,_, Figure_NP shows_VBZ the_DT percentage_NN mortality_NN rate_NN (_( with_IN 95_CD %_NN CI_NP )_) observed_VBD in_IN our_PP$ study_NN ,_, together_RB with_IN the_DT rates_NNS found_VBN in_IN four_CD previous_JJ studies_NNS ._SENT Figure_NP 1_CD |_SYM Percentage_NN mortality_NN rate_NN (_( with_IN 95_CD %_NN CI_NP )_) of_IN patients_NNS with_IN sepsis_NN :_: comparison_NN between_IN the_DT results_NNS of_IN our_PP$ observational_JJ study_NN and_CC those_DT reported_VBD in_IN the_DT four_CD RCTs_NNS previously_RB published_VBN ._SENT Percentage_NN mortality_NN rate_NN (_( with_IN 95_CD %_NN CI_NP )_) of_IN patients_NNS with_IN sepsis_NN :_: comparison_NN between_IN the_DT results_NNS of_IN our_PP$ observational_JJ study_NN and_CC those_DT reported_VBD in_IN the_DT four_CD RCTs_NNS previously_RB published_VBN ._SENT Solid_JJ lines_NNS ,_, treatment_NN groups_NNS ;_: broken_VBN lines_NNS ,_, control_NN groups_NNS ;_: dates_NNS of_IN publication_NN :_: 1993_CD ,_, Fourrier_NP et_FW al._FW ;_: early_RB 1998_CD ,_, Eisele_NP et_FW al._FW ;_: late_RB 1998_CD ,_, Baudo_NP et_FW al._FW ;_: 2001_LS ,_, Warren_NP et_FW al._FW and_CC our_PP$ study_NN ._SENT Table_NP 2_CD |_SYM Relationship_NN between_IN clinical_JJ indication_NN for_IN the_DT use_NN of_IN ATIII_NP and_CC outcome_NN of_IN hospitalization_NN Subgroup_NN analyses_NNS within_IN the_DT patient_JJ cohort_NN of_IN our_PP$ study_NN did_VBD not_RB identify_VB any_DT relationship_NN between_IN mortality_NN and_CC patient_NN characteristics_NNS ._SENT The_DT administration_NN of_IN heparin_NN ,_, which_WDT Warren_NP et_FW al._FW found_VBN to_TO have_VB some_DT implications_NNS for_IN outcome_NN ,_, did_VBD not_RB influence_VB mortality_NN in_IN our_PP$ patient_JJ series_NN :_: mortality_NN was_VBD 19.6_CD %_NN in_IN the_DT 107_CD patients_NNS who_WP received_VBD heparin_NN ,_, compared_VBN with_IN 30.5_CD %_NN in_IN the_DT 95_CD patients_NNS who_WP did_VBD not_RB receive_VB this_DT drug_NN (_( P_NN =_SYM 0.10_CD )_) by_IN Fisher_NP 's_POS exact_JJ test_NN ;_: mortality_NN was_VBD 28.6_CD %_NN in_IN the_DT 28_CD patients_NNS with_IN sepsis_NN who_WP received_VBD heparin_NN ,_, compared_VBN with_IN 42.3_CD %_NN in_IN the_DT 26_CD patients_NNS with_IN sepsis_NN who_WP did_VBD not_RB receive_VB this_DT drug_NN (_( P_NN =_SYM 0.39_CD )_) ._SENT The_DT main_JJ scientific_JJ value_NN of_IN our_PP$ observational_JJ and_CC prospective_JJ study_NN lies_VBZ in_IN its_PP$ naturalistic_JJ design_NN ;_: the_DT population_NN of_IN patients_NNS that_IN we_PP studied_VBD was_VBD in_IN fact_NN drawn_VBN from_IN the_DT everyday_JJ practice_NN of_IN more_JJR than_IN 20_CD hospitals_NNS and_CC was_VBD intentionally_RB free_JJ from_IN specific_JJ exclusion_NN criteria_NNS ._SENT In_IN interpreting_VBG our_PP$ outcome_NN data_NNS ,_, one_CD disadvantage_NN is_VBZ that_IN the_DT group_NN treated_VBN with_IN ATIII_NP was_VBD not_RB compared_VBN with_IN any_DT reference_NN group_NN observed_VBD prospectively_RB within_IN our_PP$ research_NN ;_: neither_CC did_VBD we_PP include_VBP any_DT retrospective_JJ control_NN group_NN not_RB treated_VBN with_IN the_DT drug_NN ._SENT However_RB ,_, historical_JJ retrospective_JJ controls_NNS would_MD have_VB raised_VBN profound_JJ problems_NNS of_IN matching_VBG the_DT retrospective_JJ data_NNS with_IN the_DT prospective_JJ ones_NNS ._SENT A_DT prospective_JJ enrollment_NN of_IN controls_NNS not_RB treated_VBN with_IN ATIII_NP was_VBD not_RB feasible_JJ because_IN the_DT therapeutic_JJ policy_NN of_IN the_DT ICUs_NN involved_VBN in_IN our_PP$ study_NN was_VBD to_TO administer_VB ATIII_NP to_TO virtually_RB all_DT patients_NNS with_IN a_DT diagnosis_NN of_IN sepsis_NN or_CC DIC_JJ ._SENT Regardless_RB of_IN our_PP$ statistical_JJ indexes_NNS ,_, a_DT '_'' first-look_NN '_POS comparison_NN between_IN the_DT data_NNS on_IN sepsis_NN produced_VBN by_IN the_DT previous_JJ RCTs_NP (_( including_VBG four_CD treatment_NN groups_NNS and_CC four_CD control_NN groups_NNS )_) and_CC those_DT observed_VBD in_IN our_PP$ naturalistic_JJ study_NN indicates_VBZ a_DT complete_JJ overlap_VBP of_IN the_DT various_JJ survival_NN rates_NNS and_CC of_IN their_PP$ respective_JJ 95_CD %_NN CIs_NP ._SENT This_DT qualitative_JJ impression_NN is_VBZ in_IN agreement_NN with_IN the_DT meta-analysis_NN shown_VBN in_IN Figure_NN (_( see_VB Appendix2_JJ for_IN details_NNS of_IN its_PP$ methodology_NN )_) ._SENT Figure_NP 2_CD |_SYM Comparison_NN of_IN death_NN rates_NNS between_IN patients_NNS given_VBN ATIII_NP and_CC patients_NNS given_VBN placebo_NN in_IN the_DT four_CD RCTs_NNS that_WDT met_VBD the_DT inclusion_NN criteria_NNS of_IN out_IN meta-analysis_NN ._SENT Comparison_NN of_IN death_NN rates_NNS between_IN patients_NNS given_VBN ATIII_NP and_CC patients_NNS given_VBN placebo_NN in_IN the_DT four_CD RCTs_NNS that_WDT met_VBD the_DT inclusion_NN criteria_NNS of_IN out_IN meta-analysis_NN ._SENT The_DT odds_NNS ratios_NNS of_IN the_DT individual_JJ studies_NNS and_CC of_IN our_PP$ meta-analysis_NNS are_VBP denoted_VBN by_IN dots_NNS and_CC by_IN a_DT diamond_NN ,_, respectively_RB ;_: each_DT horizontal_JJ bar_NN indicates_VBZ the_DT 95_CD %_NN CI_NP for_IN the_DT odds_NNS ratio_NN ,_, and_CC the_DT vertical_JJ dotted_JJ line_NN represents_VBZ the_DT identity_NN line_NN ._SENT From_IN top_NN to_TO bottom_NN ,_, datasets_NNS are_VBP the_DT trials_NNS of_IN Warren_NP et_FW al._FW ,_, Baudo_NP et_FW al._FW ,_, Eisele_NP et_FW al._FW ,_, and_CC Fourrier_NN et_FW al._FW ;_: the_DT bottom_JJ dataset_NN is_VBZ our_PP$ meta-analysis_NN ._SENT In_IN the_DT four_CD RCTs_NP ,_, the_DT crude_JJ death_NN rates_NNS in_IN the_DT treatment_NN group_NN and_CC in_IN the_DT control_NN group_NN ,_, respectively_RB ,_, were_VBD as_RB follows_VBZ :_: Fourrier_JJ et_FW al._FW ,_, 7_CD of_IN 17_CD versus_CC 9_CD of_IN 18_CD ;_: Eisele_NP et_FW al._FW ,_, 5_CD of_IN 20_CD versus_CC 9_CD of_IN 22_CD ;_: Baudo_NP et_FW al._FW ,_, 31_CD of_IN 50_CD versus_CC 33_CD of_IN 48_CD ;_: Warren_NP et_FW al._FW ,_, 450_CD of_IN 1157_CD versus_CC 448_CD of_IN 1157_CD ._SENT This_DT meta-analysis_NN gave_VBD the_DT following_VBG results_NNS :_: summary_NN odds_NNS ratio_NN 0.98_CD ;_: 95_CD %_NN CI_NP 0.83_CD --_: 1.15_CD ,_, P_NN =_SYM 0.80_CD ;_: chi2_NN for_IN heterogeneity_NN 1.86_CD ;_: 3_CD degrees_NNS of_IN freedom_NN ;_: P_NN =_SYM 0.60_CD ._SENT In_IN this_DT meta-analysis_NN ,_, the_DT large-scale_JJ trial_NN by_IN Warren_NP et_FW al._FW outweighed_VBD the_DT other_JJ three_CD small_JJ RCTs_NNS in_IN that_DT Warren_NP 's_POS trial_NN included_VBD 93_CD %_NN of_IN the_DT overall_JJ cohort_NN of_IN the_DT four_CD RCTs_NP ._SENT In_IN the_DT light_NN of_IN the_DT above_JJ data_NNS ,_, there_EX seems_VBZ to_TO be_VB no_DT clinical_JJ benefit_NN in_IN administering_VBG ATIII_NP to_TO critical_JJ patients_NNS with_IN sepsis_NN ;_: in_IN this_DT context_NN ,_, one_CD crucial_JJ point_NN is_VBZ that_IN the_DT most_RBS recent_JJ large-scale_JJ trial_NN gave_VBD very_RB clear_JJ results_NNS and_CC was_VBD negative_JJ ._SENT The_DT other_JJ clinical_JJ indications_NNS reported_VBN in_IN our_PP$ patients_NNS '_POS series_NN were_VBD more_RBR difficult_JJ to_TO interpret_VB because_IN of_IN the_DT nearly_RB complete_JJ lack_NN of_IN previous_JJ controlled_VBN studies_NNS exploring_VBG these_DT therapeutic_JJ issues_NNS ._SENT There_EX has_VBZ been_VBN a_DT lively_JJ debate_NN in_IN the_DT literature_NN on_IN the_DT relative_JJ merits_NNS of_IN observational_JJ studies_NNS and_CC RCTs_NNS in_IN providing_VBG useful_JJ evidence_NN of_IN clinical_JJ effectiveness_NN ._SENT Although_IN the_DT great_JJ majority_NN of_IN researchers_NNS stick_VBP to_TO the_DT concept_NN that_IN RCTs_NNS are_VBP the_DT gold_JJ standard_NN ,_, common_JJ sense_NN suggests_VBZ that_IN having_VBG information_NN both_CC from_IN RCTs_NP and_CC from_IN observational_JJ studies_NNS is_VBZ better_RBR than_IN having_VBG information_NN from_IN RCTs_NP only_RB ._SENT In_IN this_DT framework_NN ,_, our_PP$ study_NN advances_NNS knowledge_NN about_IN the_DT use_NN of_IN ATIII_NP in_IN critical_JJ patients_NNS ._SENT In_IN conclusion_NN ,_, our_PP$ findings_NNS based_VBN on_IN an_DT observational_JJ prospective_JJ study_NN and_CC on_IN an_DT updated_VBN meta-analysis_NN of_IN the_DT previous_JJ RCTs_NP do_VBP not_RB support_VB the_DT use_NN of_IN this_DT drug_NN in_IN ICU_NP patients_NNS with_IN sepsis_NN ._SENT Antithrombin_NP III_NP (_( ATIII_NP )_) is_VBZ a_DT recognized_VBN treatment_NN for_IN patients_NNS with_IN congenital_JJ ATIII_NP deficiency_NN ;_: in_IN contrast_NN ,_, the_DT evidence_NN supporting_VBG its_PP$ use_NN for_IN other_JJ clinical_JJ indications_NNS is_VBZ uncertain_JJ ._SENT In_IN Italian_JJ hospitals_NNS this_DT drug_NN is_VBZ widely_RB used_VBN in_IN patients_NNS admitted_VBN to_TO intensive_JJ care_NN units_NNS (_( ICUs_NP )_) ,_, who_WP are_VBP generally_RB given_VBN ATIII_NP for_IN the_DT treatment_NN of_IN sepsis_NN or_CC disseminated_VBN intravascular_JJ coagulation_NN ._SENT Three_CD small_JJ randomized_VBN studies_NNS and_CC one_CD large_JJ international_JJ trial_NN have_VBP assessed_VBN the_DT effectiveness_NN of_IN ATIII_NP in_IN sepsis_NN ,_, but_CC none_NN of_IN these_DT trials_NNS has_VBZ found_VBN a_DT significant_JJ benefit_NN in_IN terms_NNS of_IN reduced_VBN morbidity_NN or_CC mortality_NN ._SENT Our_PP$ findings_NNS ,_, based_VBN on_IN an_DT observational_JJ prospective_JJ study_NN and_CC on_IN an_DT updated_VBN meta-analysis_NN of_IN the_DT previous_JJ randomized_VBN controlled_JJ trials_NNS ,_, do_VBP not_RB support_VB the_DT use_NN of_IN this_DT drug_NN in_IN ICU_NP patients_NNS without_IN congenital_JJ deficiency_NN ._SENT In_IN 2001_CD our_PP$ research_NN group_NN received_VBD a_DT grant_NN from_IN Eli-Lilly_NP (_( Italy_NP )_) to_TO conduct_VB an_DT original_JJ study_NN on_IN factors_NNS influencing_VBG length_NN of_IN stay_NN in_IN critical_JJ patients_NNS with_IN sepsis_NN ._SENT In_IN Italy_NP ,_, anti-thrombin_NP III_NP is_VBZ marketed_VBN by_IN Aventis-Behring_NP and_CC by_IN Baxter_NP ._SENT Gruppo_NP di_FW Studio_NP sull'antitrombina_NP III_NP (_( The_DT Antithrombin_NN Study_NP Group_NP )_) :_: The_DT Antithrombin_NN Study_NP Group_NP includes_VBZ the_DT study_NN coordinators_NNS (_( A_DT Messori_NP ,_, F_NP Vacca_NP ,_, M_NP Vaiani_NP ,_, S_NP Trippoli_NP ,_, Laboratorio_NP di_FW Farmacoeconomia_NP ,_, c/o_NP Azienda_NP Ospedaliera_NP Careggi_NP ,_, Firenze_NP )_) and_CC a_DT total_NN of_IN 51_CD participants_NNS ._SENT The_DT names_NNS and_CC addresses_NNS of_IN the_DT participants_NNS involved_VBN in_IN the_DT project_NN were_VBD the_DT following_VBG (_( all_DT located_VBN in_IN Italy_NP )_) :_: R_NP Banfi_NP ,_, M_NP Cecchi_NP ,_, E_NP Cini_NP ,_, D_NP Dupuis_NP ,_, T_NN Falai_NP ,_, R_NP Fornaini_NP ,_, A_DT Ipponi_NP ,_, ML_NP Migliaccio_NP ,_, F_NP Pelagotti_NP ,_, L_NP Rabatti_NP ,_, I_NP Ruffino_NP ,_, R_NP Silvano_NP ,_, E_NP Tendi_NP (_( Firenze_NP ,_, four_CD hospitals_NNS )_) ;_: P_NN Becagli_NP ,_, M_NP Monciatti_NP (_( Empoli_NP )_) ;_: B_NP Bozzone_NP ,_, R_NP Casullo_NP ,_, F_NP Cattel_NP ,_, S_NP Pardossi_NP ,_, R_NP Passera_NP ,_, S_NP Stecca_NP ,_, U_NP Tagliaferro_NP (_( Torino_NP ,_, two_CD hospitals_NNS )_) ;_: P_NN Di_NP Bartolomeo_NP ,_, T_NN Faggiano_NP ,_, M_NP Lattarulo_NP (_( Bari_NP )_) ;_: N_NP Caboni_NP ,_, A_DT Cannas_NP (_( Cagliari_NP )_) ;_: A_NP Plescia_NP ,_, M_NP Sorci_NP (_( Rimini_NP )_) ;_: L_NP Bonistalli_NP ,_, M_NP Puliti_NP (_( Prato_NP )_) ;_: B_NP Ciammitti_NP ,_, M_NP Costantini_NP ,_, F_NP Mammini_NP (_( Terni_NP )_) ;_: L_NP De_NP Cicco_NP ,_, G_NP Mazzaferro_NP (_( Napoli_NP )_) ;_: P_NN Marrone_NP ,_, R_NP Tetamo_NP (_( Palermo_NP )_) ;_: P_NN Beneduce_NN ,_, MG_NP Celeste_NP ,_, P_NN Fiorani_NP ,_, S_NP Galeassi_NP ,_, G_NP Guaglianone_NP ,_, A_DT Pecere_NP ,_, L_NP Ragni_NP (_( Roma_NP ,_, two_CD hospitals_NNS )_) ;_: SM_NP Germinario_NP (_( Andria_NP )_) ;_: O_NP Basadonna_NP ,_, L_NP Todesco_NP (_( Camposampiero_NP ,_, Padova_NP )_) ;_: R_NP Calle-gari_NP ,_, M_NP Pegoraro_NP (_( Asolo_NP )_) ;_: E_NP Lamura_NP (_( Ancona_NP )_) ._SENT Methodology_NN of_IN the_DT meta-analysis_NN :_: A_DT MedLine_NP search_NN (_( PubMed_NP ,_, )_) was_VBD performed_VBN to_TO cover_VB the_DT period_NN from_IN January_NP 1980_CD to_TO November_NP 2001_CD ._SENT The_DT search_NN was_VBD limited_VBN to_TO the_DT studies_NNS published_VBN in_IN English_NP and_CC was_VBD based_VBN on_IN four_CD index_NN terms_NNS combined_VBN with_IN the_DT following_VBG Boolean_NP syntax_NN :_: "_`` antithrombin_NP III_NP "_'' AND_CC (_( sepsis_NN OR_NN septic_JJ shock_NN OR_NN "_'' disseminated_VBN intravascular_JJ coagulation_NN "_'' )_) ._SENT This_DT search_NN was_VBD supplemented_VBN by_IN examining_VBG the_DT Drugdex_NP databank_NP (_( CD-ROM_NP Drugdex_NP ,_, volume_NN 110_CD ;_: Micromedex_NP ,_, Englewood_NP ,_, Colorado_NP ,_, USA_NP )_) ._SENT Eligible_JJ studies_NNS were_VBD included_VBN if_IN they_PP met_VBD the_DT following_VBG criteria_NNS :_: patients_NNS were_VBD admitted_VBN to_TO an_DT ICU_NP ;_: randomized_VBN design_NN ;_: diagnosis_NN of_IN sepsis_NN ,_, septic_JJ shock_NN or_CC DIC_JJ ;_: assessment_NN of_IN survival_NN ._SENT The_DT odds_NNS ratio_NN was_VBD used_VBN as_IN the_DT main_JJ index_NN to_TO assess_VB the_DT treatment_NN effect_NN within_IN each_DT trial_NN and_CC to_TO generate_VB the_DT overall_JJ results_NNS of_IN the_DT meta-analysis_NN ._SENT The_DT calculation_NN of_IN the_DT summary_NN odds_NNS ratios_NNS was_VBD based_VBN on_IN a_DT random-effect_JJ model_NN ._SENT Heterogeneity_NN was_VBD assessed_VBN as_IN described_VBN previously_RB ._SENT ATIII_NN =_SYM antithrombin_NP III_NP ;_: CI_NP =_SYM confidence_NN interval_NN ;_: DIC_NP =_SYM disseminated_VBN intravascular_JJ coagulation_NN ;_: ICU_NP ,_, intensive_JJ care_NN unit_NN ;_: RCT_NP =_SYM randomized_VBN controlled_JJ trial_NN ._SENT 